These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 18474540)
1. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540 [TBL] [Abstract][Full Text] [Related]
2. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547 [TBL] [Abstract][Full Text] [Related]
3. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643 [TBL] [Abstract][Full Text] [Related]
4. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Nassar A; Cohen C; Siddiqui M Diagn Cytopathol; 2009 Dec; 37(12):865-70. PubMed ID: 19530101 [TBL] [Abstract][Full Text] [Related]
5. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780 [TBL] [Abstract][Full Text] [Related]
6. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Manion E; Hornick JL; Lester SC; Brock JE Am J Clin Pathol; 2011 Jun; 135(6):845-51. PubMed ID: 21571957 [TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155 [TBL] [Abstract][Full Text] [Related]
8. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644 [TBL] [Abstract][Full Text] [Related]
9. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067 [TBL] [Abstract][Full Text] [Related]
10. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740 [TBL] [Abstract][Full Text] [Related]
11. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615 [TBL] [Abstract][Full Text] [Related]
12. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Wludarski SC; Bacchi CE Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):466-70. PubMed ID: 18633320 [TBL] [Abstract][Full Text] [Related]
13. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Bilous M; Morey A; Armes J; Cummings M; Francis G Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651 [TBL] [Abstract][Full Text] [Related]
15. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. Bánkfalvi A; Giuffrè G; Ofner D; Diallo R; Poremba C; Buchwalow IB; Barresi V; Böcker W; Tuccari G Int J Oncol; 2003 Nov; 23(5):1285-92. PubMed ID: 14532967 [TBL] [Abstract][Full Text] [Related]
16. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803 [TBL] [Abstract][Full Text] [Related]
18. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291 [TBL] [Abstract][Full Text] [Related]
19. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741 [TBL] [Abstract][Full Text] [Related]
20. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]